Department of Clinical Sciences
Contact Information: Email: firstname.lastname@example.org; Phone: 607-253-3100
Sponsor: NIH-National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Grant Number: 1 K08 AR060875-01A1
Title: Equine iPS Cells and Their Ability to Enhance Tendon Regeneration in vivo
Annual Direct Cost: $99,665
Project Period: 05/01/2012-04/30/2017
DESCRIPTION (provided by applicant): This application seeks support for a specialty board certified (ACVS) equine veterinarian to complete the final stages of preparation for her career as a translational clinical scientist in the fields of stem cell biology and regenerative medicine. The applicant will work in the Cornell University induced Pluripotent Stem (iPS) Cell Core Laboratory under the guidance of the her mentor, Dr. Lisa A. Fortier, and collaborator, Dr. John C. Schimenti. Dr. Fortier is a scientist and large animal orthopedic surgeon who is well established in the fields of tendon repair and stem cell therapies. Dr. Schimenti is regarded as an expert in the fields of genetics and stem cell biology. Both have outstanding records for training graduate students and mentoring postdoctoral candidates and the overall research environment at Cornell is unique and eminently qualified to train translational scientists. The proposal is divided into two phases, a mentored phase and a transition phase into an independent research investigator.
During Phase I, the applicant will complete her Ph.D. and seek to broaden her knowledge base and skill set to develop a deeper understanding of the basic biology of iPS cells, including their immunogenic and immunomodulatory properties compared to mesenchymal stem cells (MSCs). The applicant and her mentor have assembled a team of immunology collaborators, Drs. Douglas Antczak, Julia Felippe (Flaminio), and Cynthia Leifer, to advise the applicant during this mentored phase and help her learn the valuable immunology concepts and methods needed to complete these studies and understand their biological significance.
In Phase II the applicant will apply the knowledge and skills learned in Phase I to complete a proof-of-principle in vivo study examining the early and late biological responses of diseased tendon to iPS cell and MSC treatment and the regenerative potential of iPS cells and MSCs for tendon repair. For these studies, we will use the well established equine model of tendonitis which has been extensively used by our research group. These experiments will test the hypothesis that iPS cells will have similar immunogenic and immunomodulatory properties as MSCs but superior regenerative potential because they are pluripotent stem cells whereas MSCs are not. This information is clinically important for determining which stem cell type should be applied therapeutically in the treatment of tendon diseases.
The expectation of this proposal is that the applicant will gain the necessary laboratory research, scientific, and management skills necessary to establish a niche in the field of regenerative medicine as an independent clinician scientist in an academic environment.